Polycystic ovary syndrome (PCOS), a common endocrine and metabolic disorder, is related to hyperandrogenism and anovulation (
1,
2). The exact pathophysiology of this condition is not completely understood; in this condition, exaggerated gonadotrophin-releasing hormone pulsatility leads to hypersecretion of luteinizing hormone (LH) and causes increased ovarian androgen production and impaired oocyte development (
3,
4). Moreover, environmental factors, including nutrition or lifestyle, can influence the expression of PCOS (
3,
5).
Polycystic ovary syndrome is associated with behavioral alterations. Studies reported that women with PCOS are at a higher risk of depression (
6,
7). On the other hand, the risk of mood and anxiety disorder is significantly higher in PCOS women, and they may show symptoms of generalized anxiety disorder, social phobia, and panic disorder (
8). Data showed that memory dysfunction and cognitive deficits might occur in PCOS patients due to alteration in brain structures (
9). So, finding a suitable approach seems important to encounter these problems.
There are different experimental models of PCOS, including estradiol valerate-induced PCOS, dehydroepiandrosterone-induced PCOS, dihydrotestosterone-induced PCOS, and letrozole-Induced PCOS (
10,
11). These models provide valuable information about the pathophysiology of PCOS and have the potential to accelerate the development of curative treatments.